Scientists issue critical warning after linking common appliance to major health risk: 'The problem is far worse than we thought'
For the first time, researchers are now able to link premature deaths to gas stove pollution. While previous studies have identified the dangers of gas stoves, this groundbreaking review has tied thousands of early deaths to the popular stoves.
A new study estimates that 40,000 deaths in Europe are a result of gas stove pollution, according to Euronews.
Researchers at the University of Jaume I's School of Health Sciences in Spain analyzed dozens of health studies examining how nitrogen dioxide causes asthma and premature deaths. They then scaled up nitrogen dioxide measurements in and outside homes across multiple European countries to establish a clear image of the pollution from gas cookers.
While research from the past 50 years has identified the health risks of nitrogen dioxide pollution, the new findings paint a much darker reality than expected.
"The extent of the problem is far worse than we thought, with our modeling suggesting that the average home across half of Europe breaks WHO limits," lead author of the new study, Dr. Juana Maria Delgado-Saborit, told Euronews. "Outdoor air pollution lays the foundation for those breaches, but it is gas cookers that push homes into the danger zone."
This is the first scientific review to have the data necessary to pinpoint premature deaths due to gas stove pollution. Although the study's findings tie 40,000 premature deaths to nitrogen dioxide exposure, it's important to note that the researchers believe this number to be much higher.
Gas stoves release harmful pollutants that can cause severe health risks as well as environmental damage. On top of exacerbating asthma, the pollutants from gas stoves also exacerbate rising global temperatures.
To avoid indoor pollution from gas cookers, homeowners across the globe are switching to induction stovetops. Unlike gas stoves, induction stoves release no harmful pollutants into the air, keeping you and your family safe.
Induction stoves are also more efficient, saving you energy and money down the line. For homeowners looking to make the switch, induction stoves from brands like Copper offer an easy and affordable solution for avoiding the dangers of gas stoves. What's more, under the Inflation Reduction Act, homeowners can receive up to 30% off the cost of an induction range.
Do you think gas stoves should be banned nationwide?
No way
Let each state decide
I'm not sure
Definitely
Click your choice to see results and speak your mind.
After switching to an induction stove, you'll notice that you won't spend as much time cooking and cleaning your kitchen since induction stoves cook faster and are easier to maintain than gas stoves.
Moving forward, it's best to act sooner rather than later when it comes to making eco-friendly upgrades to your home. President Donald Trump has stated he intends to remove these subsidies, though this would ultimately require an act of Congress. As a result, upgrading now could be the difference between saving thousands of dollars down the line.
Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Biovica Announces Financial Targets Following Key Partnerships and Commercial Progress
UPPSALA, SE / / June 10, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, today announces financial goals for the upcoming two fiscal years. The targets reflect the company's recent commercial momentum and its long-term commitment to transparency and value creation for patients, healthcare providers, and shareholders. The recently communicated partner agreement with Tempus AI in the U.S. and the agreement with a leading healthcare provider, which was communicated in December 2024, are expected to generate significant revenues for Biovica. Along with more than 15 active collaborations with pharmaceutical companies representing a total project value of approximately 25 MSEK and the 18 active partnership agreements covering key European markets, the company has established a strong foundation for growth. On this basis, Biovica is now in a position to provide clear financial guidance. Biovica's financial targets: FY 2024/25 (ending April 30, 2025): Net sales of SEK 8.5 million FY 2025/26: Net sales of SEK 50 million FY 2026/27: Net sales of SEK 150 million With expected operating expenses at the current level of approximately 90 MSEK per year, Biovica anticipates becoming cash-flow positive during the third quarter of FY 2026/27. The expected distribution of revenues during FY25/26 and FY 26/27 are: 65% from the U.S. market, driven by reimbursement and volume growth through strategic partnerships 30% from pharma services, based on ongoing and future biomarker collaborations 5% from European partners, through distributor and lab agreements across 18 territories "These targets reflect the solid groundwork we have laid over the past years," says Anders Rylander, CEO of Biovica. "We've achieved clinical validation through world-leading oncologists and institutions, received FDA clearance, established a CMS/Medicare price, initiated commercial sales, and now secured strategic partnerships that enable us to scale up. The pieces are in place to deliver on our vision-improving outcomes for patients, optimizing care for providers, and generating long-term value for shareholders." Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: This information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-06-10 18:31 CEST. Attachments Biovica announces financial targets following key partnerships and commercial progress SOURCE: Biovica International View the original press release on ACCESS Newswire
Yahoo
an hour ago
- Yahoo
Odyssey bails on public listing as US IPO landscape stutters
Odyssey Therapeutics is unlikely to join the 2025 class of biotechs hitting the stock exchanges after the company withdrew its registration statement for an initial public offering (IPO). The autoimmune and inflammatory disease specialist was one in a wave of biotechs to reveal IPO ambitions in January 2025. While Sionna Therapeutics, a biopharma that filed IPO paperwork at the same time, went on to close a nearly $220m IPO in February, Odyssey has bailed on a public listing. Odyssey did not disclose the number of its common stock shares it was offering, nor the price at which the IPO would conduct on each share. The Form S-1, a registration form with the US Securities and Exchange Commission (SEC) for companies carrying out public offerings, only mentioned that the listing would have occurred on the Nasdaq. Odyssey was eyeing an IPO as a way to fund its pipeline, headed by RIPK2 inhibitor OD-07656 that was set for Phase II trials for ulcerative colitis treatment, both as a monotherapy and in combination with Takeda's blockbuster Entyvio (vedolizumab). As per its IPO prospectus in January, the monotherapy trial was set to commence in Q1 2025, with the combo trial slated for the same quarter in 2026. Two pre-clinical programmes also stood to benefit from cash generated from the IPO. In its notice to the SEC outlining the withdrawal of the registration statement, Odyssey stated it is because it is 'not in the best interests of the company to conduct the proposed offering at this time'. The IPO U-turn is the first sign that the health of the IPO landscape could be suffering in the wake of economic fallout from US President Donald Trump's policies. Indeed, it consolidates predictions made by one GlobalData analyst earlier this year. In April, GlobalData business fundamentals analyst Alison Labya said: 'The Trump administration has introduced uncertainty to the biopharmaceutical industry across healthcare policies, drug pricing reforms, and regulatory frameworks, all of which could impact investor confidence. 'Additionally, Trump's recent tariff announcement on imports from Canada, Mexico, and China has led to increased market volatility, potentially delaying IPOs as investors await the countries' responses to the tariffs.' Biotech IPOs saw a strong recovery in 2024, with a total raise of $8.52bn, up 68.4% from $5.06bn raised in 2023. It was the highest total IPO value raised since 2021, with the rebound driven by US Federal Reserve interest rate cuts. The uptick continued into 2025, with Sionna joined by Maze Therapeutics and Metsera Therapeutics. U-turning on IPOs is rare, but Odyssey is not the only biotech to bail on a public listing in the past year. Australian biotech Telix Pharmaceuticals withdrew its US public listing at the last minute in June 2024, also citing unfavourable market conditions at the time. "Odyssey bails on public listing as US IPO landscape stutters" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Federal budget bill could strip 300K Pennsylvanians of Medicaid coverage, push rural hospitals to the brink
This story was produced by the State College regional bureau of Spotlight PA, an independent, nonpartisan newsroom dedicated to investigative and public-service journalism for Pennsylvania. Sign up for Talk of the Town, a weekly newsletter of local stories that dig deep, events, and more from north-central PA, at HARRISBURG — President Donald Trump's 'big, beautiful' budget bill could have a disastrous effect on the health of rural Pennsylvanians and the operations of the hospitals and other medical centers that care for them. The federal budget proposal, which passed the U.S. House by a one-vote margin in May, calls for nearly $800 billion in Medicaid cuts over the next decade. It also includes a new 80-hour-per-month work or service requirement for Medicaid recipients between the ages of 19 and 64 who aren't caregivers or who have disabilities. Among other changes, the bill would require verification of coverage eligibility every six months rather than annually. While supporters of the budget bill argue that it will slow spending and safeguard government programs, critics say the cuts and new requirements will create more paperwork for states and make it harder to access essential care. Opponents also argue the changes would push struggling rural hospitals and other providers to the brink, and force them to scale back services or close entirely. More than 3 million people in Pennsylvania — 23% — are covered by Medicaid, according to data from the state Department of Human Services, which administers the program. The agency estimates that more than 300,000 would lose Medicaid coverage under the proposal. Val Arkoosh, secretary of the department, said the bill would not only hurt those losing coverage but 'all of us who would face the real-life consequences of crowded emergency departments, increases in the cost of health insurance, and the catastrophic effects on economies and health systems in rural areas.' More than 737,000 Medicaid recipients live in rural counties, where residents are typically older and more reliant on government-funded insurance programs. Such programs reimburse at lower rates compared to private insurance companies and haven't kept up with inflation. Cameron County Commissioner James Moate, a Republican, said the Medicaid reimbursement rate should have never been less than 100%. 'That's why we have struggling hospitals,' he told Spotlight PA. On average, Pennsylvania hospitals absorb a loss of 18 cents on the dollar for care provided to Medicaid patients, said Nicole Stallings, president and CEO of the Hospital and Healthsystem Association of Pennsylvania, which represents more than 230 hospitals statewide. In rural communities, the average loss is 26 cents on the dollar, she added in a May statement. 'Medicaid plays a vital role in the health of rural residents, and it is important to preserve this funding so that families can continue to access the care they need for healthier lives,' said Douglas Winner, chief financial officer for Penn Highlands Healthcare, a nonprofit system with nine hospitals in rural counties. Penn Highlands President and CEO Steve Fontaine has told lawmakers that consolidating with other health systems and expanding into new areas has helped facilities survive. This strategy, which has helped Penn Highlands diversify its patient and insurance bases, is why the system expanded into Centre County, where resident numbers are expected to grow, he told lawmakers last year. Still, the health system has shuttered services and reported operating losses over the past year. Winner said Penn Highlands is 'greatly concerned' about the proposed Medicaid cuts. 'Rural hospitals have experienced substantial cost increases for labor, drugs, and supplies,' he said in a statement. 'Coupled with decreasing volumes, inadequate reimbursement rates, and ongoing staffing shortages — recruitment and retention — we are struggling financially.' Advocates worry the cuts in the federal budget will force rural hospitals to slash services even more or close altogether. And once facilities end a service or shut down, they rarely reopen, Stallings told Spotlight PA. Community health centers could also be strained. These facilities, also known as federally qualified health centers, provide services regardless of someone's ability to pay and primarily see patients who use Medicaid and PENNIE, the state's Affordable Care Act marketplace. More uninsured people will likely lead to an increase in uncompensated care, said Eric Kiehl, director of policy and partnership for the Pennsylvania Association of Community Health Centers. And these facilities are already strapped for resources, he told Spotlight PA. A surge in demand could cause these health centers to shutter core services — such as medical, dental, or behavioral health — reduce hours, or close, Kiehl said. Pennsylvania's U.S. House delegation voted along party lines on the federal budget bill, with Republicans supporting and Democrats opposing the proposal. Medicaid spending totaled roughly $44 billion in fiscal year 2023. The federal government provided almost $28 billion of those dollars. Democratic Gov. Josh Shapiro has said the state won't be able to make up those dollars to support the Medicaid program. In a statement, Shapiro said he hopes 'common sense and a concern for the people of Pennsylvania' will prevail in the U.S. Senate, where Democratic U.S. Sen. John Fetterman and Republican U.S. Sen. Dave McCormick disagree on aspects of the bill. McCormick did not respond to a request for comment for this story. He has expressed support for the budget bill, which he says will reduce and slow government spending. During a Fox News forum, McCormick said he isn't advocating for taking benefits from 'vulnerable people' but is trying to ensure 'people for whom the program was designed' benefit. Fetterman called the plan 'a bad bill,' telling Spotlight PA in a statement: 'Republicans want to put more money in the pockets of the ultra-rich at the expense of hundreds of thousands of Pennsylvanians who will lose access to Medicaid if this disastrous bill is passed.' and help us reinvigorate local news in north-central Pennsylvania at Spotlight PA is funded by foundations and readers like you who are committed to accountability and public-service journalism that gets results. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
